Navigation Links
Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:9/21/2007

s to Subjects with Severe Renal Impairment"

Cethromycin at 300 mg QD for five days was well tolerated by both subjects with severe renal impairment and with normal renal function. Elevated drug exposure observed for subjects with severe renal impairment suggest that these patients should be monitored when taking cethromycin.

The following poster presentations discussed cethromycin as a potential treatment for CAP, particularly when resistance to other treatments is known:

"Assessment of In Vitro Activity of Cethromycin Against Telithromycin-resistant Strains of Streptococcus Pneumoniae"

All eight clinical Streptococcus pneumoniae isolates were resistant to erythromycin with MICs > 128 micron g/mL and had telithromycin MICs >/= 2 micron g/mL. For six of these isolates, the cethromycin MIC was at least 8-fold lower than the telithromycin MIC, for another isolate the MICs were the same, and for the other the telithromycin MIC was one doubling dilution lower than the cethromycin MIC.

Cethromycin maintained good in vitro potency against a collection of telithromycin-resistant S. pneumoniae isolates. This finding suggests that underlying resistance mechanisms that result in reduced telithromycin susceptibility do not affect cethromycin to the same extent. Therefore, cethromycin continues to represent a reasonable potential therapeutic option for S. pneumoniae of this phenotype.

"Assessment of In Vitro Activity of Cethromycin Against Strains of Streptococcus Pneumoniae"

Cethromycin demonstrated potent in vitro activity against all Streptococcus pneumoniae populations studied, regardless of their resistance phenotype. Based on MIC90 data collected, cethromycin was 2-4 times more potent than telithromycin and 10-12 times more potent than the macrolides studied. These findings demonstrate that cethromycin has the potential to be a potent therapeutic option for the treatment of CAP, even for infections caused by strains resistant to cu
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
3. Phase III Clinical Trial with 4-Month Long-Acting Formulation of Triptorelin: Ipsen Decides Not to Perform Further Administration
4. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
5. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
6. Liponex Inc. Reports Further Analysis of CRD5 Phase I/II Clinical Trial Data
7. MIV Therapeutics Announces Pivotal Test Results Further Validating Company Stent Coatings Meet Critical FDA Fatigue Guidelines
8. Managing Preanalytical Processes for Patient Safety
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... , UNION CITY, Calif., Nov. 25 /PRNewswire-Fir...l products company manufacturing point-of-care blo...verson, chairman and chief executive officer, will...are Conference on Wednesday, December 2, 2009 at 2...w York Palace Hotel in New York City. ,, About...
(Date:11/25/2009)... , NEW YORK, Nov. 25 Re...h report is available in its catalogue: ,, Pa...reportlinker.com/p0164220/Pain-Management---Global...eric drugs, emergence of pain management clinics, ...ace of growth in the pain management market. Healt...
(Date:11/24/2009)... , BETHESDA, Md., Nov. 24 /PRNewswir... (Nasdaq: CHDX ), a leading independent American ...es in the People,s Republic of China, today,announ...iper Jaffray,"Unplugged" Health Care Conference, t...lace Hotel. , Management is currently sch...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6Chindex International to Present at Piper Jaffray Health Care Conference 2Kill the cancer not the patient 3A New toxicity testing approach could make chemo drugs safer 10789 1Kill the cancer not the patient 3A New toxicity testing approach could make chemo drugs safer 10789 2IWillAgain com Launches Online Community for Athletes Overcoming Accident Illness or Injury 61623 1IWillAgain com Launches Online Community for Athletes Overcoming Accident Illness or Injury 61623 2HCA Names Joe Sowell Senior Vice President 26amp 3B Chief Development Officer 61620 1HCA Names Joe Sowell Senior Vice President 26amp 3B Chief Development Officer 61620 2
...c. today,announced positive Phase 2 data for the C...ss aminomethylcycline (AMC). The Phase 2 study com...(IV) forms of PTK 0796 to,Zyvox(R) in the treatmen...ture infections (cSSSIs). Paratek,s trial met its ...ating no differences between PTK 0796 and,Zyvox in...
...maceuticals plc (AIM: MPM), the drug development c...c disorders, is pleased to announce positive,resul...t in the prevention,of migraine with aura. The med....01) in patients receiving tonabersat when compare...t of the study is both clinically and,statisticall...
Other Medicine Technology:Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Paratek Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 2Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura 3
(Date:11/28/2009)... CHICAGO, Nov. 28 Welcome to s...ion for the clinical routine from Siemens Health...nications System (PACS) from Siemens where 2D, 3...yngo .plaza is poised to change the way multimod...this innovation at the 95th Scientific Assembly ...
(Date:11/28/2009)... tips to help lift spirits, recognize signs of dep... News) -- For many seniors, the holiday season can... ones, struggle with health issues or worry about ...cs Society. , To help overcome the seasonal blu...the following advice: , Get out and socialize or...
(Date:11/27/2009)...ALLAS, Nov. 27 Consider...ure only 25 years ago, solid organ transplantation...to the extraordinary men and women who gathered at...aders came together from medical centers around th...r Regional Transplant Institute (BRTI), one of the...
(Date:11/27/2009)...BBUTZ SHAMIR, Israel, Nov. 27 /PRNewswire-FirstCal...) ( "Shamir" ), a leading provider of innovative p...et, announced today that its board of directors ha... amount of US$ 10 million (approximately NIS 37.62...tive rate of exchange), or approximately US$ 0.609...
(Date:11/27/2009)... , SEATTLE, Nov. 27 A...ed record-high Thanksgiving traffic numbers, with ...ksgiving, providing a clear picture of what was se...average Thanksgiving meal in 2009 weighed in at 2,...m last year,s feast. According to the Allrecipes s...
Breaking Medicine News(10 mins):Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 2Health News:Siemens Healthcare Unveils syngo.plaza at RSNA 2009 3Health News:Seniors May Need Help Overcoming Holiday Blues 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4
...rapy used to treat advanced breast cancer in postm... increase// in overall survival when compared to o...atic review of studies. In addition, aromat...s, said review co-author Judith Bliss of the Insti...
...tute have discovered new details about how bacteri...ed papers//, the scientists add key specifics to t...uses cholera. The work could provide a better unde... As a single-cell organism, Vibrio cholerae ...
...ne that influences how severe a M. pneumoniae infe...ent strategy// might be needed for treating asthma...ather than allergies. "What this shows is t... Robert Hardy, an infectious disease specialist at...
...rug’s development, the Florey and Starfish Venture... formed// a start-up company, ‘Nephrodynamics Pty ...ntracts a bacterial infection after surgery. It is...ring septic shock can require dialysis for up to t...
...ego, reporting their proceedings on PNAS Journal’s...ed// a virtual human metabolic network that will g...ments for hundreds of human metabolic disorders, f...d contains more than 3,300 known human biochemical...
...used by weightlifters and sprinters to improve ath...eople with// muscular dystrophies. Muscle st...g patients taking creatine, compared to those who ...sers. The evidence from the studies “shows t...
Other Medicine News:Health News:Hormone Drug Type Makes Survival Difference in Advanced Breast Cancer 2Health News:Hormone Drug Type Makes Survival Difference in Advanced Breast Cancer 3Health News:How Bacteria Generate Energy to Live? 2Health News:How Bacteria Generate Energy to Live? 3Health News:Different Treatments Needed For Breathing Problems 2Health News:Research on Human Metabolic Disorders 2Health News:Research on Human Metabolic Disorders 3Health News:Creatine Supplement May Help People With Muscular Dystrophies 2
Finnpipette Focus Fixed Volume, 500ul
Ovation BioNatural Pipette, one-stroke, fixed volume, 300L
...Reference Series 2000 Pipette is a synonym for pip...bust design, and superior operating comfort. Its s...he measuring stroke and blow-out as well as eject ...system ensures utmost accuracy and precision. Ejec...
...Reference Series 2000 Pipette is a synonym for pip...bust design, and superior operating comfort. Its s...he measuring stroke and blow-out as well as eject ...system ensures utmost accuracy and precision. Ejec...
Medicine Products: